CH
SEEL

CVI Holdings’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

CVI Holdings’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15
Closed -$54K – 48
2019
Q3 		$54K Buy
+15
New +$90.4K 0.12% 25

Other funds holding SEEL

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CVI Holdings's SEEL Position: Q4 2019 in Review

CVI Holdings sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2019, closing a stake of 15 shares — an estimated $54K sold.

CVI Holdings first reported a position in SEEL in Q3 2019 and held it in 1 quarter. The position peaked at $54K in Q3 2019. 13 funds tracked by Wall St. Rank hold SEEL as of Q4 2019.

  • CVI Holdings reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • CVI Holdings sold 15 Seelos Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $54K.
  • CVI Holdings first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • CVI Holdings's Seelos Therapeutics, Inc. Common Stock position peaked at $54K in Q3 2019.
  • 13 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2019.

Based on CVI Holdings's 13F filing for Q4 2019, filed 14 Feb 2020.